Next Generation Viral Vector Safety Webinar
Of the 1902 assets currently captured on Beacon Gene Therapy, nearly 60% leverage AAV’s. With this choice, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be. Join us online to be part of the solution to bringing safer, effective genetic therapies to patients and gain immediately implementable data insights to sharpen your programs currently in development.
This webinar will uncover analysis on:
- Preclinical models leveraged to assess safety of viral vectors
- Immunogenicity information from historic and ongoing trials
- Insights into the reason for recent clinical holds in the viral delivery space
Our Experts
Farrah Vogel-Javeri
House Speaker
Lead Research Analyst
Beacon
Matty Slingsby
Moderator
Account Manager
Beacon
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
